文｜财华社 医械企业如何布局减肥赛道？ 在全球生活方式改变、城市化及人口老龄化的驱动下，包括肥胖症、代谢功能障碍相关脂肪性肝炎（MASH）及2型糖尿病（T2DM）在内的代谢性疾病 已成为一项普遍的全球健康挑战，并为医疗器械领域创造了规模最大且增长最快的机遇之一。 成立于2016年的糖吉医疗是一家立足于中国的医疗器械公司，专注于为代谢性疾病的治疗及全周期管理提供创新解决方案，旨在提供有别于药物治疗及侵 入性减重手术的独特治疗方法。 在业务布局上，糖吉医疗形成了"核心产品+关键产品+配套器械+数字健康"的多元化管线：核心产品胃转流支架系统（GBS）已实现商业化；关键产品包 括针对MASH的GBS-SH（获FDA突破性器械认定）、针对2型糖尿病的GBS-DM，以及可降解胃内球囊（DIGB）、可取出收胃内球囊（RIGB）；配套器 械涵盖电子胃镜、内镜回收套件等；数字健康平台Dtx与临床营养食品则完善了全周期管理闭环。 | | FINE | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | ...

骨科医生李志疆，难得高调一回。 2月上旬，他签发公告宣布，其骨科髋关节手术导航系统设备，已中标浙大医学院附属第一医院，进入国内顶尖的三甲医院。 同时，李志疆公布2024年12月以来的6个中标项目，涵盖北京大学第三医院等知名机构，其过往较少主动披露业务进展。 | | 中標結果 / | | | --- | --- | --- | | 招標者 | 簽約日期 | 中標公告價格 | | | | (人民幣元) | | · 山東省立醫院 | 2024年12月 | 446萬(附註) | | · 青島市中醫醫院(市海慈醫院) | 2025年08月 | 680萬 | | · 北京大學第三醫院 | 2025年11月 | 830萬 | | · 北京某著名大型三級甲等醫院 | 2026年01月 | 未公佈 | | · 浙江大學醫學院附屬第一醫院 | 2026年01月 | 398萬 | | · 山東某醫院 | 2026年01月 | 未公佈 | 李是骨科医生出身，2003年创办爱康医疗，一路缔造国内人工关节领域的领军企业，至2月16日市值逼近70亿港元。 据称，平均每两分钟，就有一例爱康假体被植入。 李志疆已不满足在关节耗材的突破，其正大 ...

微创心通-B(02160)涨超6%，截至发稿，涨6.33%，报0.84港元，成交额859.92万港元。 消息面上，2月13日晚，微创心通发布公告称，近日，国家药品监督管理局"NMPA"医疗器械技术审评 中心发布《创新医疗（002173）器械特别审查申请审查结果公示(2026年第3号)》，拟同意集团旗下新 一代植入式心律转复除颤器(ICD)TILEN/EYLEN(泰然╱怡然)进入创新医疗器械特别审查程序(NMPA绿 色通道)。据此，TILEN/EYLEN(泰然╱怡然)有望成为国内首款获批的具备自主知识产权的磁共振条件 安全ICD。 ...

消息面上，2月13日晚，微创心通发布公告称，近日，国家药品监督管理局"NMPA"医疗器械技术审评 中心发布《创新医疗器械特别审查申请审查结果公示(2026年第3 号)》，拟同意集团旗下新一代植入式 心律转复除颤器(ICD)TILEN/EYLEN (泰然╱怡然)进入创新医疗器械特别审查程序(NMPA绿色通道)。 据此 ，TILEN/EYLEN(泰然╱怡然)有望成为国内首款获批的具备自主知识产权的磁共振条件安全 ICD。 微创心通-B(02160)涨超6%，截至发稿，涨6.33%，报0.84港元，成交额859.92万港元。 ...

微创机器人主要提供用于微创手术的手术机器人，其中"图迈"及"鸿鹄"分别为其在腹腔镜及骨科领域的 核心产品。"图迈"是首款经临床验证疗效不逊于达文西手术系统的中国国产腹腔镜手术机器人，而达文 西手术系统乃直觉外科公司(Intuitive Surgical)目前在中国及全球的领先产品。该行相信此项成就确立了 微创机器人作为中国本土龙头企业的地位，使其能够受惠于进口替代趋势。 摩根大通发布研报称，予微创机器人-B(02252)"增持"评级，目标价为41港元。微创机器人核心产品"图 迈"累计订单已突破200台，意味自2026年1月下旬以来新增约20台订单，延续2025年10月至2026年1月的 强劲势头，持续缓解市场对其可持续性的部分担忧。覆盖范围已扩展至逾50个国家及地区(2025年12月 底为40多个)，其中12个市场订购超过五台，主要由新兴市场如印度及巴西领军，而西班牙、澳洲等发 达市场亦取得加速突破。 ...

微创机器人主要提供用于微创手术的手术机器人，其中"图迈"及"鸿鹄"分别为其在腹腔镜及骨科领域的 核心产品。"图迈"是首款经临床验证疗效不逊于达文西手术系统的中国国产腹腔镜手术机器人，而达文 西手术系统乃直觉外科公司(Intuitive Surgical)目前在中国及全球的领先产品。该行相信此项成就确立了 微创机器人作为中国本土龙头企业的地位，使其能够受惠于进口替代趋势。 智通财经APP获悉，摩根大通发布研报称，予微创机器人-Ｂ(02252)"增持"评级，目标价为41港元。微 创机器人核心产品"图迈"累计订单已突破200台，意味自2026年1月下旬以来新增约20台订单，延续2025 年10月至2026年1月的强劲势头，持续缓解市场对其可持续性的部分担忧。覆盖范围已扩展至逾50个国 家及地区(2025年12月底为40多个)，其中12个市场订购超过五台，主要由新兴市场如印度及巴西领军， 而西班牙、澳洲等发达市场亦取得加速突破。 ...

Core Viewpoint - Spring Medical (01858) has announced a significant increase in its expected net profit for the fiscal year 2025, with projections indicating a rise of 96.01% to 130.41% year-on-year, driven by improvements in its core business and international expansion efforts [1][4]. Financial Performance - The company anticipates a net profit attributable to shareholders of between 245 million to 288 million yuan for 2025, and a non-recurring net profit of 230 million to 270 million yuan, reflecting increases of 96.01% to 130.41% and 142.80% to 185.11% respectively [1][4]. - In Q1 of the previous year, Spring Medical reported a revenue of 230 million yuan, marking a 3.6% increase, and a net profit of 58 million yuan, up 5.2% [7]. - By Q3 of the previous year, the company achieved a revenue of 756 million yuan, a year-on-year growth of 48.75%, and a net profit of 192 million yuan, a significant increase of 213.21% [7]. Market Reaction - Despite the positive earnings forecast, the market response has been muted, with the stock price declining by 2.87% the day after the announcement and continuing to fall, reaching a low of 13.47 HKD [4][10]. - The stock has experienced a maximum fluctuation of over 30% since hitting a peak of 20.49 HKD in early November [4][10]. Business Drivers - The growth in profits is attributed to the gradual release of growth potential following the inclusion of various product lines in centralized procurement, alongside the company's ongoing international development strategy [5][18]. - The overseas revenue contribution reached 40% in the first half of the previous year, indicating a strong international market presence [18]. Valuation - Following a three-month decline in stock price, Spring Medical's overall valuation has fallen below the industry average, with a current PE ratio of 19.12, compared to the industry average of 20.48 [11]. - The stock is considered undervalued, with a 6% lower PE ratio than its average over the past three months [11]. Investor Sentiment - Recent data indicates that the Hong Kong Stock Connect funds have shifted from being net buyers to net sellers of Spring Medical shares, with significant sell-offs observed [13][15]. - The holding ratio of Hong Kong Stock Connect funds decreased from a peak of 47.77% to 43.16%, reflecting a change in investment strategy towards trend-based trading [15].

Core Viewpoint - A newly approved non-invasive treatment for locally advanced pancreatic cancer, utilizing a wearable device to continuously deliver electric fields that disrupt tumor cell division, has gained attention. This treatment, approved by the FDA for use in the U.S., is not yet available in China but offers insights for domestic professionals [2]. Group 1: Treatment Mechanism - The Optune Pax system employs Tumor Treating Fields (TTFields) technology, delivering low-intensity alternating electric fields to the tumor area via electrode arrays attached to the skin [3]. - The core mechanism of action is that the electric field affects rapidly dividing cancer cells while having a limited impact on normal cells, which divide more slowly [4][5]. Group 2: Device Characteristics - Optune Pax is a lightweight and portable system, allowing patients to receive treatment while maintaining daily activities [6]. - The device applies physical forces to charged cellular structures, disrupting spindle formation during mitosis, blocking chromosome separation, and leading to cancer cell death [7]. Group 3: Clinical Trial Results - The approval of Optune Pax is based on the pivotal Phase III clinical trial PANOVA-3, which demonstrated a significant improvement in overall survival [9]. - In the intention-to-treat population, the median overall survival was 18.3 months for the treatment group compared to 15.1 months for the control group, indicating a clinically meaningful improvement [10]. - The one-year survival rate was 68.1% for the treatment group versus 60.2% for the control group [11]. - Patients experienced delayed progression of pain and improved quality of life indicators, with the treatment showing good overall tolerability [12]. Group 4: Challenges and Future Considerations - Despite positive clinical trial results, real-world application faces challenges, including balancing efficacy and treatment burden, which will directly impact its adoption [17]. - Key observations for future development include the need for real-world data to validate the long-term value of TTFields in pancreatic cancer treatment [18]. - The treatment landscape for pancreatic cancer has seen little innovation over decades, making this development noteworthy [19].

Core Viewpoint - Dexcom, a leader in continuous glucose monitoring (CGM), reported Q4 2025 revenue of $1.26 billion, a 13% year-over-year increase, and a net profit of $267 million, up over 70%, indicating a shift in growth structure driven by product cycle upgrades, treatment ecosystem integration, and algorithm capabilities [1][4][16]. Group 1: Financial Performance - The company has entered a profit release phase, with profit growth significantly outpacing revenue growth, as evidenced by a gross margin increase to 63% and improved operating profit margins [4][5]. - The revenue for Q4 2025 was $1.26 billion, with a gross profit of $792.7 million, reflecting a strong financial performance [6]. Group 2: Growth Drivers - The first growth driver is the upgrade in wear cycle, particularly with the launch of the G7 15-day version, which enhances user convenience and increases annual value per user [7]. - The second driver involves the integration with insulin pump companies, transforming CGM from a data collection tool to a core data source for automated insulin delivery systems, increasing user retention [8]. - The third driver is the regulatory approval for algorithm-based insulin dose optimization, marking a shift from data collection to decision support, enhancing the commercial value of CGM [9][10]. Group 3: Industry Context - The global CGM market is experiencing high growth, but competition is solidifying, with leading companies establishing strong barriers through technological advancements and ecosystem integration [12]. - The competition is shifting from accuracy to comprehensive capabilities, with smaller companies facing pressure if they lack differentiation [13]. Group 4: Implications for Domestic Companies - Domestic CGM companies should focus on building data platforms and system integration capabilities rather than solely hardware manufacturing to achieve long-term breakthroughs [15].

Group 1: Market Updates - The Hang Seng Index will increase its constituent stocks from 88 to 90, adding CATL, Luoyang Molybdenum, and Laopu Gold [1] - The Dow Jones Industrial Average rose by 48.95 points to 49,500.93, a gain of 0.1%, while the S&P 500 increased by 3.41 points to 6,836.17, a rise of 0.05%. The Nasdaq Composite fell by 50.48 points to 22,546.67, a decline of 0.22% [2] - Gold and silver futures both rose over 2%, with gold prices surpassing $5,000, closing at $5,063.80 per ounce, and silver at $77.27 per ounce [3] Group 2: Regulatory Developments - The State Administration for Market Regulation issued the "Antitrust Compliance Guidelines for Internet Platforms," aimed at clarifying the boundaries of competitive behavior for platform operators [4] - The Financial Regulatory Bureau, in conjunction with the Market Regulation Bureau and the People's Bank of China, held discussions with six travel platform companies regarding compliance in lending practices [5] - The People's Bank of China and the Financial Regulatory Bureau released a list of 21 systemically important banks, categorized into five groups based on their importance scores [6] Group 3: Industry Performance - In January, the national port equipment operating rate was 33.85%, an increase of 2.97 percentage points year-on-year, indicating strong demand in foreign trade [7] - SF Holding reported a total revenue of 26.86 billion yuan in January, a year-on-year increase of 2.22%, driven by growth in supply chain and international logistics [9] - Sands China Limited reported a net profit of $896 million for 2025, a decrease of 14.3%, while total revenue increased by 5.1% to $7.44 billion [10] Group 4: Technological Advancements - MIKRON Heart Technology announced that its new generation implantable cardioverter-defibrillator (ICD) is entering the special review process for innovative medical devices, potentially becoming the first domestically approved MRI-safe ICD [8] - The release of the national certification standard for automotive steering systems is seen as a significant step towards the mass production of steer-by-wire technology, which offers advantages such as improved cabin space and enhanced driving comfort [11]